Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3092Neoplasms 2436Carcinoma, Non-Small-Cell Lung 1863Prostatic Neoplasms 1617Colorectal Neoplasms 1422Lung Neoplasms 1292Multiple Myeloma 927Neoplasm Metastasis 919Leukemia, Myeloid, Acute 874Pancreatic Neoplasms 847Ovarian Neoplasms 799Melanoma 783Carcinoma, Hepatocellular 736Stomach Neoplasms 639Brain Neoplasms 635Recurrence 633Squamous Cell Carcinoma of Head and Neck 630Head and Neck Neoplasms 609Glioblastoma 566Lymphoma 539Uterine Cervical Neoplasms 537Triple Negative Breast Neoplasms 504Precursor Cell Lymphoblastic Leukemia-Lymphoma 499Carcinoma, Renal Cell 497Hematologic Neoplasms 462Urinary Bladder Neoplasms 459Endometrial Neoplasms 459Colonic Neoplasms 441Lymphoma, Non-Hodgkin 435Sarcoma 434

Interventions

Specimen Handling 2Taxes 1Paclitaxel 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Cyclophosphamide 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Breast Adenocarcinoma × 1 year × Clear all
NCT00433511 2026-05-29

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
4,994 enrolled 11 charts
Breast

Breast Adenocarcinoma

NCT04517838 2025-12-24

Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer

Mayo Clinic

Recruiting
230 enrolled
Breast

Breast Adenocarcinoma

NCT05447910 2025-06-15

Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer

Mayo Clinic

Terminated
21 enrolled
Breast

Breast Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡